IBB — iShares Biotechnology ETF
In 2026 Q2, 7 of the 140 tracked hedge funds reported a position in iShares Biotechnology ETF (IBB), worth $10.29M combined. Over the quarter 4 opened or added, 2 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Renaissance | $4.20M | 0.00% | +256.5% |
| QVT | $3.52M | 0.23% | NEW |
| Westwood | $1.26M | 0.36% | +29.4% |
| Navellier | $531.39K | 0.04% | NEW |
| Chapin Davis | $395.03K | 0.07% | NO CHANGE |
| Dale Q Rice | $380.95K | 0.21% | -14.3% |
| Barnes Dennig | $2.85K | 0.00% | NO CHANGE |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.